Please try another search
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Joseph S. McCracken | 71 | 2013 | Lead Independent Director |
Francesco Bonella | - | - | Member of Clinical Advisory Board |
Matthew Pauls | 53 | 2017 | Chairman & CEO |
Nevan Charles Elam | 57 | 2009 | Independent Director |
Richard J. Hawkins | 75 | 2010 | Independent Director |
David A. Ramsay | 59 | 2017 | Independent Director |
Yoshikazu Inoue | - | - | Member of Clinical Advisory Board |
Bruce C. Trapnell | - | - | Member of Clinical Advisory Board |
Tisha Wang | - | 2023 | Member of Clinical advisory Board |
Cormac McCarthy | - | 2021 | Member of Clinical Advisory Board |
An van Es-Johansson | 64 | 2019 | Independent Director |
Ricky Lijing Sun | 50 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review